Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
The projected business potential is around US$ 1 million in the first year
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Subscribe To Our Newsletter & Stay Updated